Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches

References

• Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006;113:2011-20
   PubMed Web of Science ®Google Scholar
• Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev 2010;19:59-63
   PubMedGoogle Scholar
• Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000;15:440-8
   PubMed Web of Science ®Google Scholar
• Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation 2014;130:508-18
   PubMed Web of Science ®Google Scholar
• Freeman LM. Don’t bury the V/Q scan: it’s as good as multidetector CT angiograms with a lot less radiation exposure. J Nucl Med 2008;49:5-8
   PubMedGoogle Scholar
• LeVarge BL, Channick RN. Chronic thromboembolic pulmonary hypertension: evolution in management. Curr Opin Pulm Med 2014;20:400-8
   PubMedGoogle Scholar
• Pepke-Zaba J, Jansa P, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J 2013;41:985-90
   PubMedGoogle Scholar
• Shigeta A, Tanabe N, Shimizu H, et al. Gender differences in chronic thromboembolic pulmonary hypertension in Japan. Circ J 2008;72:2069-74
   PubMedGoogle Scholar
• Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54:S85-96
   PubMed Web of Science ®Google Scholar
• Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:608-14
   PubMedGoogle Scholar
• Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993;103:685-92
   PubMed Web of Science ®Google Scholar
• Alias S, Redwan B, Panzenbock A, et al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014;34:810-19
   PubMed Web of Science ®Google Scholar
• Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003;90:372-6
   PubMed Web of Science ®Google Scholar
• Wolf M, Boyer-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15:395-9
   PubMed Web of Science ®Google Scholar
• Wong CL, Szydlo R, Gibbs S, et al. Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 2010;21:201-6
   PubMed Web of Science ®Google Scholar
• Olman MA, Marsh JJ, Lang IM, et al. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992;86:1241-8
   PubMedGoogle Scholar
• Lang IM, Marsh JJ, Olman MA, et al. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994;89:2715-21
   PubMedGoogle Scholar
• Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013;41:462-8
   PubMed Web of Science ®Google Scholar
• Ogawa A, Firth A, Yao W, et al. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009;297:L666-76
   PubMed Web of Science ®Google Scholar
• Sakao S, Hao H, Tanabe N, et al. Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir Res 2011;12:109
   PubMedGoogle Scholar
• Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:1211-18
   PubMed Web of Science ®Google Scholar
• Langer F, Schramm R, Bauer M, et al. Cytokine response to pulmonary thromboendarterectomy. Chest 2004;126:135-41
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Gunther S, Ghigna MR, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J 2014;44:1275-88
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973-81
   PubMed Web of Science ®Google Scholar
• Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:568-70
   PubMedGoogle Scholar
• Morris TA, Marsh JJ, Chiles PG, et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006;173:1270-5
   PubMed Web of Science ®Google Scholar
• Kato F, Tanabe N, Urushibara T, et al. Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension. Cir J 2014;78:1754-61
   Google Scholar
• Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009;114:1929-36
   PubMed Web of Science ®Google Scholar
• Chen Z, Nakajima T, Tanabe N, et al. Susceptibility to chronic thromboembolic pulmonary hypertension may be conferred by miR-759 via its targeted interaction with polymorphic fibrinogen alpha gene. Hum Genet 2010;4:443-52
   Google Scholar
• Kominami S, Tanabe N, Ota M, et al. HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic thromboembolic pulmonary hypertension in the absence of deep vein thrombosis. J Hum Genet 2009;(2):108-14
   PubMedGoogle Scholar
• Tanabe N, Kimura A, Amano S, et al. Association of clinical features with HLA in chronic pulmonary thromboembolism. Eur Respir J 2005;(1):131-8
   PubMedGoogle Scholar
• Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33:325-31
   PubMed Web of Science ®Google Scholar
• Kim NH, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2012;21:27-31
   PubMedGoogle Scholar
• Condliffe R, Kiely DG, Gibbs JS, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33:332-8
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
   PubMed Web of Science ®Google Scholar
• Group JCSJW. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011;75:1258-81
   PubMedGoogle Scholar
• Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680-4
   PubMed Web of Science ®Google Scholar
• Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013;62:D92-9
   PubMed Web of Science ®Google Scholar
• Tanabe N, Sugiura T, Tatsumi K. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. Respir Invest 2013;51:134-46
   PubMedGoogle Scholar
• Geyer LL, Scherr M, Korner M, et al. Imaging of acute pulmonary embolism using a dual energy CT system with rapid kVp switching: initial results. Eur J Radiol 2012;81:3711-18
   PubMedGoogle Scholar
• Dournes G, Verdier D, Montaudon M, et al. Dual-energy CT perfusion and angiography in chronic thromboembolic pulmonary hypertension: diagnostic accuracy and concordance with radionuclide scintigraphy. Eur Radiol 2014;24:42-51
   PubMed Web of Science ®Google Scholar
• Ley S, Ley-Zaporozhan J, Pitton MB, et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2012;22:607-16
   PubMed Web of Science ®Google Scholar
• Thistlethwaite PA, Kaneko K, Madani MM, et al. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg 2008;14:274-82
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1122-7
   PubMed Web of Science ®Google Scholar
• Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 2001;103:10-13
   PubMed Web of Science ®Google Scholar
• Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009;54:S67-77
   PubMed Web of Science ®Google Scholar
• Fukui S, Ogo T, Goto Y, et al. Exercise intolerance and ventilatory inefficiency improve early after balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol 2015;180:66-8
   PubMedGoogle Scholar
• Shimura N, Kataoka M, Inami T, et al. Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2015;183:138-42
   PubMedGoogle Scholar
• Yanagisawa R, Kataoka M, Inami T, et al. Safety and efficacy of percutaneous transluminal pulmonary angioplasty in elderly patients. Int J Cardiol 2014;175:285-9
   PubMedGoogle Scholar
• Inami T, Kataoka M, Shimura N, et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv 2013;6:725-36
   PubMed Web of Science ®Google Scholar
• Inami T, Kataoka M, Shimura N, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 2014;7:1297-306
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012;5(6):748-55
   PubMed Web of Science ®Google Scholar
• Roik M, Wretowski D, Łabyk A, et al. Optical coherence tomography of inoperable chronic thromboembolic pulmonary hypertension treated with refined balloon pulmonary angioplasty P. Pol Arch Med Wewn 2014;124(12):742-3
   PubMed Web of Science ®Google Scholar
• Roik M, Wretowski D, Rowiński O, et al. Refined balloon pulmonary angioplasty in inoperable chronic thromboembolic pulmonary hypertension--a multi-modality approach to the treated lesion. Int J Cardiol 2014;177(3):e139-41
   PubMedGoogle Scholar
• Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;15:640-8
   PubMed Web of Science ®Google Scholar
• Jais X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006;28:138-43
   PubMed Web of Science ®Google Scholar
• Becattini C, Manina G, Busti C, et al. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 2010;126:e51-6
   PubMed Web of Science ®Google Scholar
• Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93-9
   PubMed Web of Science ®Google Scholar
• Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007;26:357-62
   PubMed Web of Science ®Google Scholar
• Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. Vasc Health Risk Manag 2008;4:507-13
   PubMedGoogle Scholar
• Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5:483-9
   PubMed Web of Science ®Google Scholar
• Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43
   PubMed Web of Science ®Google Scholar
• Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134:229-36
   PubMed Web of Science ®Google Scholar
• Toshner MR, Gopalan D, Suntharalingam J, et al. Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2010;29:610-15
   PubMedGoogle Scholar
• Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008;21:824-32
   PubMed Web of Science ®Google Scholar
• Buckley MS, Staib RL, Wicks LM, et al. Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. Drug Healthc Patient Saf 2010;2:151-61
   PubMedGoogle Scholar
• Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-9
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369:319-29
   PubMed Web of Science ®Google Scholar
• Mielniczuk LM, Swiston JR, Mehta S. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Can J Cardiol 2014;30:1233-40
   PubMedGoogle Scholar
• Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013;218:279-313
   PubMedGoogle Scholar
• Goncharova EA. mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J 2013;27:1796-807
   PubMedGoogle Scholar
• Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011;75:1801-10
   PubMed Web of Science ®Google Scholar
• Jasińska-Stroschein M, Owczarek J, Plichta P, Orszulak-Michalak D. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension. Pharmacology 2014;93:145-50
   PubMed Web of Science ®Google Scholar
• Pankey EA, Thammasiboon S, Lasker GF, et al. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol 2013;305:H1288-96
   Google Scholar